BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $218,488 | -49.1% | 28,673 | -33.5% | 0.00% | -50.0% |
| Q3 2022 | $429,000 | +122.3% | 43,089 | +102.4% | 0.00% | +100.0% |
| Q2 2022 | $193,000 | -70.8% | 21,286 | -67.3% | 0.00% | -50.0% |
| Q1 2022 | $661,000 | +137.8% | 65,107 | +1330.3% | 0.00% | +100.0% |
| Q2 2021 | $278,000 | -92.4% | 4,552 | -92.4% | 0.00% | -93.8% |
| Q1 2021 | $3,677,000 | -62.5% | 59,698 | -56.7% | 0.02% | -62.8% |
| Q4 2020 | $9,812,000 | +110.9% | 137,985 | +11.3% | 0.04% | +138.9% |
| Q3 2020 | $4,653,000 | +21.1% | 124,022 | +5.3% | 0.02% | -5.3% |
| Q2 2020 | $3,841,000 | – | 117,785 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |